Eli Lilly developed the diabetes and obesity drug Mounjaro, helping drive its market value higher.
Eli Lilly developed tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Strong demand and promising clinical results for this drug class contributed to major investor interest in Eli Lilly and helped make it one of the world’s most valuable pharmaceutical companies.
The company was founded in 1876 in Indianapolis by Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran. Its historic products include insulin, antibiotics, and psychiatric medicines, while its modern portfolio includes diabetes, obesity, oncology, and immunology treatments.
Mounjaro and Zepbound are not identical marketing names for unrelated medicines: both contain tirzepatide, but they have different approved uses and branding. Regulatory approval, pricing, and market value are separate issues, so a company’s stock valuation should not be treated as a clinical conclusion.